Get started
Author

Marie Toukam

Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis
2024 · John F. Foley, Gilles Defer, et al. · Neurology Neuroimmunology & Neuroinflammation · 11
PDF
ABCL-777: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2025 · Juan Pablo Alderuccio, Craig Okada, et al. · Clinical Lymphoma Myeloma & Leukemia · 10
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study
2025 · Alex F. Herrera, Stephen M. Ansell, et al. · Blood Advances · 10
PDF
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)
2024 · Heinz Wiendl, John Foley, et al. · Neurology and Therapy · 10
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma
2022 · Marie Toukam, Jens Wuerthner, et al. · Cancer Chemotherapy and Pharmacology · 7
Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma
2022 · Marie Toukam, Joseph P. Boni, et al. · Cancer Chemotherapy and Pharmacology · 5
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy
2025 · Yuezhe Li, A. Katharina Wilkins, et al. · npj Systems Biology and Applications · 3
PDF
608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
2023 · Christopher T Chen, Erika Hamilton, et al. · Regular and Young Investigator Award Abstracts · 3
PDF
CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
2022 · Jerzy Dyczkowski, Alex F. Herrera, et al. · Blood · 2
ABCL-758: Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL
2025 · Carmelo Carlo-Stella, Michal T. Kwiatek, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Abstract 4151: Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors
2022 · Igor Puzanov, Christopher T. Chen, et al. · Cancer Research · 1
Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
2026 · Ranjit Nair, Abhijeet Kumar, et al. · Blood Advances
PDF
Population PK/PD Modeling to Optimize Dosing of BIIB107, an Anti-Alpha-4 Integrin Monoclonal Antibody
2026 · Marie Toukam, Negin Karimian, et al.
Dose Optimization of BIIB107, an Anti‐Alpha‐4 Integrin Monoclonal Antibody, Through Population Pharmacokinetic and Pharmacodynamic Modeling
2025 · Marie Toukam, Negin Karimian, et al. · The Journal of Clinical Pharmacology
ORAL ABSTRACT: ABCL-777 Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2025 · Juan Pablo Alderuccio, Craig Okada, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-777 Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2025 · Juan Pablo Alderuccio, Craig Okada, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-758 Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL
2025 · Carmelo Carlo-Stella, Michal T. Kwiatek, et al. · Clinical Lymphoma Myeloma & Leukemia
Résultats de l’étude d’extension NOVA évaluant la préférence des patients pour l’administration sous-cutanée (SC) versus intraveineuse (IV) de natalizumab (NTZ) avec le schéma Q6W (toutes les 6 semaines)
2024 · Heinz Wiendl, John Foley, et al. · Revue Neurologique
Works count: 20
Citation count: 63
H-index: 5
I10-index: 4
Year
Topic
Type